WALTHAM, Mass. — February 6, 2026 — Leads & Copy — Spyre Therapeutics Inc. (NASDAQ: SYRE) announced that the company’s independent Compensation Committee of the Board of Directors approved stock options to purchase 30,200 shares of common stock to five non-executive employees.
The stock options were approved on February 2, 2026, and were material to each employee’s acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4). According to the company, Spyre is pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases.
The stock options were granted under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The options have a 10-year term and an exercise price equal to $32.75, the closing price per share of Spyre’s common stock as reported by Nasdaq on February 2, 2026.
The options granted to the employees will vest and become exercisable as to one-fourth of the shares subject to the options on the first anniversary of the employee’s start date. One-forty-eighth of the shares subject to the options will vest and become exercisable monthly thereafter, contingent on continuous service with Spyre through the applicable vesting dates. The stock options are subject to the terms of the 2018 Plan.
Spyre Therapeutics is a clinical-stage biotechnology company. Spyre’s pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.
Source: Spyre Therapeutics
